Mandelia Chetan, Collyer Elizabeth, Mansoor Sana, Lopez Rocio, Lappe Sara, Nobili Valerio, Alkhouri Naim
*Pediatric Institute †Department of Pediatric Gastroenterology ‡Digestive Disease Institute §Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH ||Liver Unit, "Bambino Gesù" Children's Hospital and Research Institute, Rome, Italy.
J Pediatr Gastroenterol Nutr. 2016 Aug;63(2):181-7. doi: 10.1097/MPG.0000000000001136.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the obesity epidemic and affects approximately 10% of children in the US. The presence of hepatic fibrosis may be the most important factor in determining the prognosis of NAFLD. Noninvasive methods to identify the presence of fibrosis in children with NAFLD are greatly needed. Hepatocyte apoptosis activates hepatic stellate cells and plays a central role in fibrosis progression in NAFLD. The aim of the present study was to evaluate the use of plasma cytokeratin-18 (CK18) fragment levels, a marker of hepatocyte apoptosis, as a noninvasive biomarker in detecting liver fibrosis in pediatric NAFLD.
Consecutive children with biopsy-proven NAFLD were included and blood samples and anthropometric measurements were collected at the time of the biopsy. NAFLD activity score was calculated (0-8) and fibrosis stage was scored (0-4). We measured plasma CK18 levels using the M30-Apoptosense enzyme-linked immunosorbent assay kit.
A total of 201 subjects were enrolled in the study. The mean age was 10.7 ± 2.5 years, and 37 % were boys. Sixty-eight percent of the patients had any fibrosis, with 56% having F1, 6% having F2, and 6 % having F3. CK18 levels were found to be significantly higher in subjects with any fibrosis compared with those without fibrosis (304.6 ± 124.8 vs 210.4 ± 70.9, P < 0.001). CK18 level revealed good accuracy for prediction of any fibrosis (F1-F3) with AUROC of 0.75. Multivariate logistic regression was performed to assess whether CK18 in combination with another clinical factor could improve accuracy of prediction of fibrosis. Together, CK18 with waist circumference percentile generated an area under the receiver operating characteristics curve of 0.842 for prediction of any fibrosis.
CK18 is a promising noninvasive biomarker for fibrosis in NAFLD in children. A fibrosis prediction model that includes CK18 and waist circumference percentile should be validated in other populations.
非酒精性脂肪性肝病(NAFLD)是肥胖流行的肝脏表现,在美国约10%的儿童受其影响。肝纤维化的存在可能是决定NAFLD预后的最重要因素。非常需要非侵入性方法来识别NAFLD儿童中纤维化的存在。肝细胞凋亡激活肝星状细胞,并在NAFLD纤维化进展中起核心作用。本研究的目的是评估血浆细胞角蛋白-18(CK18)片段水平(一种肝细胞凋亡标志物)作为检测儿童NAFLD肝纤维化的非侵入性生物标志物的用途。
纳入经活检证实为NAFLD的连续儿童,并在活检时采集血样和人体测量数据。计算NAFLD活动评分(0 - 8)并对纤维化阶段进行评分(0 - 4)。我们使用M30 - Apoptosense酶联免疫吸附测定试剂盒测量血浆CK18水平。
共有201名受试者纳入研究。平均年龄为10.7±2.5岁,37%为男孩。68%的患者有任何纤维化,其中56%为F1,6%为F2,6%为F3。发现有任何纤维化的受试者的CK18水平显著高于无纤维化者(304.6±124.8对210.4±70.9,P<0.001)。CK18水平对任何纤维化(F1 - F3)的预测具有良好的准确性,曲线下面积(AUROC)为0.75。进行多变量逻辑回归以评估CK18与另一临床因素联合是否可提高纤维化预测的准确性。CK18与腰围百分位数联合用于预测任何纤维化时,受试者操作特征曲线下面积为0.842。
CK18是儿童NAFLD纤维化的一种有前景的非侵入性生物标志物。包含CK18和腰围百分位数的纤维化预测模型应在其他人群中进行验证。